Collplant achieves milestone and to receive $10 million from abbvie in accordance with its regenerative dermal filler product collaboration agreement

Rehovot, israel , june 26, 2023 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced the achievement of a milestone with respect to the clinical phase dermal filler product, according to its agreement with abbvie for the development of a regenerative dermal and soft tissue filler product. according to the agreement, the achievement of this milestone triggers a $10 million payment from abbvie to collplant.
CLGN Ratings Summary
CLGN Quant Ranking